Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
Healthcare
$3.53 -3.40%
-$0.24 today
- Market cap
- $103.02M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
52W Low $3.71High $8.74
Volume 0.86M
Average 0.65M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$31.32M
FY 2025 · Annual
Investing Cash Flow
-$12.10M
FY 2025 · Annual
Financing Cash Flow
$46.47M
FY 2025 · Annual
+3.1% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 966K | 1.05M | 1.77M | 2.35M | 2.64M |
| Change in Working Capital | (105K) | 1.18M | (93K) | (427K) | (5.95M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.24M | 1.27M | 1.28M | 790K | (2.51M) |
| Other Working Capital | (1.35M) | (89K) | (1.37M) | (1.22M) | (3.45M) |
| Other Non-Cash Items | 3.38M | 21K | 10.3M | 5.8M | (2.02M) |
| Operating Cash Flow | (5.77M) | (15.65M) | (18.28M) | (28.58M) | (31.32M) |
| Capital Expenditures | (29K) | (2K) | (12K) | (72K) | (24K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (12.07M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (29K) | (2K) | (12K) | (72K) | (12.1M) |
| Debt Repayment | (15K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 22.27M | 11K | 0 | 683K | 48.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.1M) | 0 |
| Other Financing Activities | 119K | (482K) | (2.65M) | (4.5M) | (1.61M) |
| Financing Cash Flow | 22.38M | (471K) | 27.54M | 45.09M | 46.47M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.58M | (16.12M) | 9.25M | 16.44M | 3.06M |
| Free Cash Flow | (5.8M) | (15.65M) | (18.3M) | (28.65M) | (31.34M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$26.6M
+ D&A$572.0K
+ Stock-Based Comp$2.6M
+ Deferred Tax$0
- Working Capital-$6.0M
- Other Non-Cash-$2.0M
= Operating Cash Flow-$31.3M
- Capex-$24.0K
= Free Cash Flow-$31.3M
Analysis
FY2025 free cash flow is -$31.3M. FCF conversion is 118.0% of net income. Operating cash flow was -$31.3M, with capex of -$24.0K. The largest bridge item is Working Capital at -$6.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 29, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 1, 2026 | |
| 8-K | Current report | Sep 29, 2026 | |
| 8-K | Current report | Sep 28, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
Does UNCY generate free cash flow?
Unicycive Therapeutics, Inc. (UNCY) generated -$31.34M of free cash flow in fiscal 2025.
How much operating cash flow does UNCY produce?
Operating cash flow was -$31.32M, before capital expenditures of $24,000.00.
Continue the stock analysis
Jump to another research area for this company.